Latest News
Circassia Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology
Rapid four-dose regimen maintains significant symptom reduction one year after start of treatment
27 September 2012
Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
Newly-Created Position to Lead Commercialisation Preparations for Lead Allergy Programme
18 September 2012
Circassia Appoints Dr Brett Haumann as Chief Medical Officer
11 September 2012
Circassia’s Canadian Joint Venture With McMaster University Initiates Two Clinical Studies to Explore Biomarkers of ToleroMune® Treatment Effectiveness
Studies to investigate proteomic and genetic responses to ToleroMune therapy
09 August 2012
Did you know?
The average bed could be home to up to 1.5 million house dust mites